INOTEK PHARMACEUTICALS CORP's ticker is and the CUSIP is 45780VAB8. A total of 9 filers reported holding INOTEK PHARMACEUTICALS CORP in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $5,785,000 | +1.5% | 4,000,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $5,700,000 | -27.6% | 4,000,000 | 0.0% | 0.00% | -40.0% |
| Q4 2020 | $7,872,000 | +69.9% | 4,000,000 | 0.0% | 0.01% | +66.7% |
| Q3 2020 | $4,633,000 | +4.5% | 4,000,000 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $4,432,000 | +5.1% | 4,000,000 | 0.0% | 0.00% | -25.0% |
| Q1 2020 | $4,218,000 | -2.6% | 4,000,000 | 0.0% | 0.00% | +33.3% |
| Q4 2019 | $4,329,000 | +9.6% | 4,000,000 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $3,950,000 | -1.0% | 4,000,000 | 0.0% | 0.00% | +50.0% |
| Q2 2019 | $3,989,000 | +0.6% | 4,000,000 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $3,967,000 | +320.2% | 4,000,000 | +300.0% | 0.00% | +100.0% |
| Q4 2018 | $944,000 | -47.2% | 1,000,000 | -66.7% | 0.00% | 0.0% |
| Q2 2017 | $1,788,000 | +1.0% | 3,000,000 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $1,770,000 | -43.3% | 3,000,000 | 0.0% | 0.00% | -66.7% |
| Q4 2016 | $3,120,000 | -22.7% | 3,000,000 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $4,036,000 | – | 3,000,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TFG Asset Management GP Ltd | 7,700,000 | $8,592,000 | 1.03% |
| Bruce & Co., Inc. | 2,000,000 | $2,220,000 | 0.43% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 13,600,000 | $15,130,000 | 0.36% |
| Orbimed Advisors | 7,000,000 | $7,788,000 | 0.09% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1,000,000 | $1,108,000 | 0.08% |
| Verition Fund Management LLC | 1,633,000 | $1,826,000 | 0.06% |
| Citadel Advisors | 11,250,000 | $12,462,000 | 0.01% |
| CREDIT SUISSE AG/ | 4,750,000 | $5,239,000 | 0.01% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |